Indicated for adults with: 🍬 Type 2 Diabetes Mellitus: To improve glycemic control. ⚖️ Chronic Weight Management: For patients with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related comorbidities.

Dosage and administration

Packaging: Single-dose Vial (2.5 mg / 0.5 ml). ⚠️ DOSAGE PROTOCOL (Initiation): 💉 2.5 mg Dose: This is the starting dose used for the first 4 weeks to allow the body to adjust. It is not considered a therapeutic dose for glycemic control. 📅 Frequency: Inject subcutaneously once weekly, on the same day each week. 📍 Sites: Abdomen, thigh, or upper arm. Rotate injection sites.

Personal or family history of Medullary Thyroid Carcinoma (MTC). Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to Tirzepatide. Pregnancy and breastfeeding.

Gastrointestinal side effects are common during dose escalation: 🤢 Digestive: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia. ⚠️ Pancreatitis: Severe abdominal pain radiating to the back (rare but serious). Hypoglycemia (when used with insulin).

Mounjaro 2.5 — Tirzepatide 2.5 mg / 0.5 ml, 1 pcs, Eli Lilly

100% original product

Active ingredient

Tirzepatide

Manufacturer

Eli Lilly

Dosage 2.5 mg / 0.5 ml

Dosage form Vial

Vials per pack 1

Mounjaro 2.5 mg (Tirzepatide) 2.5 mg/0.5 mL

Name: Mounjaro 2.5
Brand: Eli Lilly
SKU: PROD-116
Price: 3164 UAH
Availability: InStock

3164₴ ~~3736₴~~ -15%

Mounjaro 2.5 mg (Tirzepatide 2.5 mg) is a breakthrough, first-in-class medication for type 2 diabetes and chronic weight management.

Manufacturer: Eli Lilly (India). Unlike other injectable weight-loss drugs that target only one hormone, Mounjaro targets two.

Mechanism of Action ("Dual GIP/GLP-1 Agonist"):

Tirzepatide activates receptors for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This synergistic effect enhances insulin secretion, suppresses glucagon levels, slows gastric emptying, and significantly reduces appetite. It essentially "reprograms" the body's metabolic set point.

✅ Key Benefit: Superior weight loss and A1C reduction compared to GLP-1 receptor agonists alone.

Indicated for adults with:

🍬 Type 2 Diabetes Mellitus: To improve glycemic control.
⚖️ Chronic Weight Management: For patients with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related comorbidities.

Packaging: Single-dose Vial (2.5 mg / 0.5 ml).

⚠️ DOSAGE PROTOCOL (Initiation):

💉 2.5 mg Dose: This is the starting dose used for the first 4 weeks to allow the body to adjust. It is not considered a therapeutic dose for glycemic control.
📅 Frequency: Inject subcutaneously once weekly, on the same day each week.
📍 Sites: Abdomen, thigh, or upper arm. Rotate injection sites.

Personal or family history of Medullary Thyroid Carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Known hypersensitivity to Tirzepatide.
Pregnancy and breastfeeding.

Gastrointestinal side effects are common during dose escalation:

🤢 Digestive: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia.
⚠️ Pancreatitis: Severe abdominal pain radiating to the back (rare but serious).
Hypoglycemia (when used with insulin).

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 18.03.2026